Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : S007-867
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Marc Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke
Details : The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.
Brand Name : S007-867
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 12, 2021
Lead Product(s) : S007-867
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Marc Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Colchicine,Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : LAXAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 pati...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2021
Lead Product(s) : Colchicine,Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : LAXAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Lee Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
CSIR-IICT Licenses Process Knowhow for Synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd.
Details : Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufact...
Brand Name : 2-DG
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 09, 2021
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Lee Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : LAXAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins
Details : The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2021
Lead Product(s) : Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : LAXAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
